Completed PHASE3 INTERVENTIONAL NCT00025818

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

Sponsor: Allergan

Conditions Arthritis, Rheumatoid Keratoconjunctivitis Sicca Lupus Erythematosus, Systemic Scleroderma, Systemic Sjogren's Syndrome

Interventions Ophthalmic Emulsion

Updated 7 times since 2017 Last updated: May 27, 2011 Started: May 31, 2001 Primary completion: Mar 31, 2003 Completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Arthritis, Rheumatoid and Keratoconjunctivitis Sicca and is currently completed. Allergan leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Brooklyn, United States , Chicago, United States , Cleveland, United States , El Paso, United States , Houston, United States , Indianapolis, United States , La Jolla, United States , Leominster, United States and 7 more locations